Clinical Significance of Tissue Factor–Exposing Microparticles in Arterial and Venous Thrombosis

 

 Buy Article Permissions and Reprints

Abstract

Microparticles (MP) are small extracellular vesicles (30–1,000 nm) that are released from activated cells or platelets. Exposure of negatively charged phospholipids and tissue factor (TF) renders MP procoagulant. Normal plasma levels of intravascular TF-exposing MP (TFMP) are low, but their number may rise in pathological conditions, including cancer and infectious disease. Emerging evidence indicates an important role for these circulating TFMP in the pathogenesis of thrombotic complications such as venous thromboembolism and disseminated intravascular coagulation, whereas their contribution to arterial thrombosis is less studied. Despite serious limitations of the currently available assays for measuring TFMP levels or the procoagulant activity associated with TFMP with respect to sensitivity and specificity, the scientific interest in TFMP is rapidly growing because their application as prognostic biomarkers for thrombotic complications is promising. Future advances in detection methods will likely provide more insight into TFMP and eventually improve their clinical utility.

• References

• 1 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
  CrossrefPubMedGoogle Scholar
• 2 Raskob GE, Angchaisuksiri P, Blanco AN , et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
  CrossrefPubMedGoogle Scholar
• 3 Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368 (21) 2004-2013
  CrossrefPubMedGoogle Scholar
• 4 Virchow R. Ueber die Erweiterung kleinerer Gefäfse. Arch Pathol Anat Physiol Klin Med 1851; 3 (3) 427-462
  CrossrefPubMedGoogle Scholar
• 5 Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012; 122 (7) 2331-2336
  CrossrefPubMedGoogle Scholar
• 6 van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012; 64 (3) 676-705
  CrossrefPubMedGoogle Scholar
• 7 Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13 (3) 269-288
  CrossrefPubMedGoogle Scholar
• 8 Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. Blood Rev 2013; 27 (1) 31-39
  CrossrefPubMedGoogle Scholar
• 9 van der Pol E, Coumans F, Varga Z, Krumrey M, Nieuwland R. Innovation in detection of microparticles and exosomes. J Thromb Haemost 2013; 11 (Suppl. 01) 36-45
  CrossrefPubMedGoogle Scholar
• 10 Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JWA, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106 (19) 2442-2447
  CrossrefPubMedGoogle Scholar
• 11 Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93 (1) 327-358
  CrossrefPubMedGoogle Scholar
• 12 Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D, Dubois C. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206 (9) 1913-1927
  CrossrefPubMedGoogle Scholar
• 13 Falati S, Liu Q, Gross P , et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197 (11) 1585-1598
  CrossrefPubMedGoogle Scholar
• 14 van der Pol E, Coumans FA, Grootemaat AE , et al. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost 2014; 12 (7) 1182-1192
  CrossrefPubMedGoogle Scholar
• 15 Arraud N, Linares R, Tan S , et al. Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost 2014; 12 (5) 614-627
  CrossrefPubMedGoogle Scholar
• 16 Khorana AA, Francis CW, Menzies KE , et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6 (11) 1983-1985
  CrossrefPubMedGoogle Scholar
• 17 Tesselaar MET, Romijn FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 2007; 5 (3) 520-527
  CrossrefPubMedGoogle Scholar
• 18 Berckmans RJ, Sturk A, van Tienen LM, Schaap MCL, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 2011; 117 (11) 3172-3180
  CrossrefPubMedGoogle Scholar
• 19 van Doormaal F, Kleinjan A, Berckmans RJ , et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108 (1) 160-165
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Tatsumi K, Antoniak S, Monroe III DM, Khorana AA, Mackman N ; Subcommittee on Hemostasis and Malignancy. Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1932-1934
  CrossrefPubMedGoogle Scholar
• 21 Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F ; The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013;
  PubMedGoogle Scholar
• 22 Hron G, Kollars M, Weber H , et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97 (1) 119-123
  Google Scholar
• 23 Campello E, Zabeo E, Radu CM , et al. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost 2015; 113 (1) 85-96
  PubMedGoogle Scholar
• 24 Lee RD, Barcel DA, Williams JC , et al. Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res 2012; 129 (1) 80-85
  CrossrefPubMedGoogle Scholar
• 25 Franz C, Böing AN, Hau CM , et al. Procoagulant tissue factor-exposing vesicles in human seminal fluid. J Reprod Immunol 2013; 98 (1–2) 45-51
  CrossrefPubMedGoogle Scholar
• 26 Berckmans RJ, Nieuwland R, Tak PP , et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002; 46 (11) 2857-2866
  CrossrefPubMedGoogle Scholar
• 27 Berckmans RJ, Nieuwland R, Böing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85 (4) 639-646
  PubMedGoogle Scholar
• 28 Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood 2013; 122 (11) 1873-1880
  CrossrefPubMedGoogle Scholar
• 29 Nieuwland R, Berckmans RJ, McGregor S , et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95 (3) 930-935
  PubMedGoogle Scholar
• 30 Baker JV, Huppler Hullsiek K, Bradford RL, Prosser R, Tracy RP, Key NS. Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr 2013; 63 (3) 367-371
  CrossrefPubMedGoogle Scholar
• 31 Matijevic N, Wang Y-WW, Wade CE , et al; PROMMTT Study Group. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res 2014; 134 (3) 652-658
  CrossrefPubMedGoogle Scholar
• 32 Bastarache JA, Fremont RD, Kropski JA, Bossert FR, Ware LB. Procoagulant alveolar microparticles in the lungs of patients with acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2009; 297 (6) L1035-L1041
  CrossrefPubMedGoogle Scholar
• 33 Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factor expressing microparticles in women with recurrent pregnancy loss. PLoS ONE 2013; 8 (11) e81407
  CrossrefPubMedGoogle Scholar
• 34 Biró E, Sturk-Maquelin KN, Vogel GMT , et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1 (12) 2561-2568
  CrossrefPubMedGoogle Scholar
• 35 Thaler J, Koppensteiner R, Pabinger I, Ay C, Gremmel T. Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thromb Res 2014; 134 (5) 1093-1096
  CrossrefPubMedGoogle Scholar
• 36 Garcia Rodriguez P, Eikenboom HCJ, Tesselaar MET , et al. Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 2010; 126 (4) 345-349
  CrossrefPubMedGoogle Scholar
• 37 Campello E, Spiezia L, Radu CM , et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127 (5) 473-477
  CrossrefPubMedGoogle Scholar
• 38 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
  CrossrefPubMedGoogle Scholar
• 39 van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119 (4) 924-932
  CrossrefPubMedGoogle Scholar
• 40 Auwerda JJA, Yuana Y, Osanto S , et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105 (1) 14-20
  PubMedGoogle Scholar
• 41 Thaler J, Koder S, Kornek G, Pabinger I, Ay C. Microparticle-associated tissue factor activity in patients with metastatic pancreatic cancer and its effect on fibrin clot formation. Transl Res 2014; 163 (2) 145-150
  CrossrefPubMedGoogle Scholar
• 42 Thaler J, Ay C, Mackman N , et al. Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012; 10 (7) 1363-1370
  CrossrefPubMedGoogle Scholar
• 43 Bharthuar A, Khorana AA, Hutson A , et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (2) 180-184
  CrossrefPubMedGoogle Scholar
• 44 Tesselaar MET, Romijn FPHTM, van der Linden IK, Bertina RM, Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009; 7 (8) 1421-1423
  CrossrefPubMedGoogle Scholar
• 45 Zwicker JI, Liebman HA, Neuberg D , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
  CrossrefPubMedGoogle Scholar
• 46 Zwicker JI, Liebman HA, Bauer KA , et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol 2013; 160 (4) 530-537
  CrossrefPubMedGoogle Scholar
• 47 Haubold K, Rink M, Spath B , et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009; 101 (6) 1147-1155
  PubMedGoogle Scholar
• 48 Manly DA, Wang J, Glover SL , et al. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res 2010; 125 (6) 511-512
  CrossrefPubMedGoogle Scholar
• 49 Sartori MT, Della Puppa A, Ballin A , et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost 2013; 110 (2) 378-385
  Article in Thieme ConnectPubMedGoogle Scholar
• 50 Hernández C, Orbe J, Roncal C , et al. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost 2013; 110 (3) 598-608
  Article in Thieme ConnectPubMedGoogle Scholar
• 51 Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370 (9) 847-859
  CrossrefPubMedGoogle Scholar
• 52 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49 (1) 5-7
  PubMedGoogle Scholar
• 53 Øvstebø R, Aass HCD, Haug KBF , et al. LPS from Neisseria meningitidis is crucial for inducing monocyte- and microparticle-associated tissue factor activity but not for tissue factor expression. Innate Immun 2012; 18 (4) 580-591
  CrossrefPubMedGoogle Scholar
• 54 Aras O, Shet A, Bach RR , et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103 (12) 4545-4553
  CrossrefPubMedGoogle Scholar
• 55 Hellum M, Øvstebø R, Brusletto BS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. Thromb Res 2014; 133 (3) 507-514
  CrossrefPubMedGoogle Scholar
• 56 Woei-A-Jin FJSH, van der Starre WE, Tesselaar MET , et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res 2014; 133 (5) 799-803
  CrossrefPubMedGoogle Scholar
• 57 Świtońska M, Słomka A, Sinkiewicz W, Żekanowska E. Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation. Eur J Neurol 2015; 22 (2) 395-e29
  CrossrefPubMedGoogle Scholar
• 58 Stępień E, Stankiewicz E, Zalewski J, Godlewski J, Zmudka K, Wybrańska I. Number of microparticles generated during acute myocardial infarction and stable angina correlates with platelet activation. Arch Med Res 2012; 43 (1) 31-35
  CrossrefPubMedGoogle Scholar
• 59 Huisse M-G, Lanoy E, Tcheche D , et al. Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thromb Haemost 2007; 98 (2) 420-426
  PubMedGoogle Scholar
• 60 Keuren JFW, Jie K-SG, Leers MPG. Increased expression of TF on monocytes, but decreased numbers of TF bearing microparticles in blood from patients with acute myocardial infarction. Eur J Haematol 2009; 83 (4) 387-388
  CrossrefPubMedGoogle Scholar
• 61 Maly M, Hrachovinova I, Tomasov P, Salaj P, Hajek P, Veselka J. Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma: a pilot study. Eur J Haematol 2009; 82 (2) 148-153
  CrossrefPubMedGoogle Scholar
• 62 Morel O, Pereira B, Averous G , et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. Atherosclerosis 2009; 204 (2) 636-641
  CrossrefPubMedGoogle Scholar
• 63 Leroyer AS, Isobe H, Lesèche G , et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007; 49 (7) 772-777
  CrossrefPubMedGoogle Scholar
• 64 Schmidt M, Cannegieter SC, Johannesdottir SA, Dekkers OM, Horváth-Puhó E, Sørensen HT. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study. J Thromb Haemost 2014; 12 (8) 1207-1215
  CrossrefPubMedGoogle Scholar
• 65 Glynn RJ, Danielson E, Fonseca FA , et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18) 1851-1861
  CrossrefPubMedGoogle Scholar
• 66 Owens III AP, Byrnes JR, Mackman N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med 2014; 24 (3) 95-98
  CrossrefPubMedGoogle Scholar
• 67 Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91 (1) 146-154
  PubMedGoogle Scholar
• 68 Owens III AP, Passam FH, Antoniak S , et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122 (2) 558-568
  CrossrefPubMedGoogle Scholar
• 69 Davila M, Robles-Carrillo L, Unruh D , et al. Microparticle association and heterogeneity of tumor-derived tissue factor in plasma: is it important for coagulation activation?. J Thromb Haemost 2014; 12 (2) 186-196
  CrossrefPubMedGoogle Scholar